Similar articles

• Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts).

  Dean J, Schechter AN. Dean J, et al. N Engl J Med. 1978 Oct 19;299(16):863-70. doi: 10.1056/NEJM197810192991605. N Engl J Med. 1978. PMID: 692579 No abstract available.
• Spin label study of hemoglobin membrane interactions in normal and sickle erythrocytes.

  Jones GL. Jones GL. Proc West Pharmacol Soc. 1979;22:79-86. Proc West Pharmacol Soc. 1979. PMID: 515098 No abstract available.
• Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts).

  Dean J, Schechter AN. Dean J, et al. N Engl J Med. 1978 Oct 5;299(14):752-63. doi: 10.1056/NEJM197810052991405. N Engl J Med. 1978. PMID: 357967 Review. No abstract available.
• Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals.

  Noguchi CT, Rodgers GP, Schechter AN. Noguchi CT, et al. Prog Clin Biol Res. 1987;240:381-91. Prog Clin Biol Res. 1987. PMID: 3615501
• Cyanate as an inhibitor of red-cell sickling.

  Cerami A. Cerami A. N Engl J Med. 1972 Oct 19;287(16):807-12. doi: 10.1056/NEJM197210192871606. N Engl J Med. 1972. PMID: 4560520 Review. No abstract available.